Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026)
Oculis Holding AG (OCS) recorded quarterly Other Non-Current Liabilities of $26.2 million in Q1 2026, up 44.81% quarter-over-quarter from $18.1 million in Q4 2025, and up 57.89% on a YoY basis from $16.6 million in Q1 2025.
Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $26.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 57.89% year-over-year to $26.2 million; the TTM figure through Mar 2026 stood at $26.2 million (up 57.89% YoY), while the FY2025 annual figure was $18.1 million, down 20.06% from the prior year.
- Other Non-Current Liabilities was $26.2 million for Q1 2026 at Oculis Holding AG, up from $18.1 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $26.2 million in Q1 2026 to a low of $426140.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $11.7 million across 4 years, with a median of $12.1 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 5217.58% in 2024, then fell 20.06% in 2025.
- A 4-year view of Other Non-Current Liabilities shows it stood at $426140.0 in 2023, then jumped by 5217.58% to $22.7 million in 2024, then fell by 20.06% to $18.1 million in 2025, then surged by 44.81% to $26.2 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $26.2 million (Q1 2026), $18.1 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.23 Mn |
| Dec 31, 2025 | 18.11 Mn |
| Sep 30, 2025 | 15.18 Mn |
| Jun 30, 2025 | 18.25 Mn |
| Mar 31, 2025 | 16.61 Mn |
| Dec 31, 2024 | 22.66 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 8.14 Mn |
| Mar 31, 2024 | 433,067.91 |
| Dec 31, 2023 | 426,139.99 |
| Sep 30, 2023 | 426,821.52 |
| Jun 30, 2023 | 4.78 Mn |